Lars‐Olof Hattenbach

Author

Also Known As

A. Agharza, C Kuhli-Hattenbach, C. Kuhli-Hattenbach, Claudia Kuhli-Hattenbach, Claudia Kuhli‐Hattenbach, Claus Gehrig, Gerd Geerling, Hansjürgen Agostini, Hattenbach, Lars-Olof, K. Strobel Bermond

261

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

Goethe University Frankfurt Klinikum Ludwigshafen University Hospital Frankfurt Ophthalmology Clinic University of Bonn

About

Lars‐Olof Hattenbach is an author at Goethe University Frankfurt specializing in medicine, ophthalmology, and thrombosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	23	1.8K
2	Public Health	1	1	72
3	Biomedical Engineering	1	1	46
4	Cell Biology	1	1	43
5	Diabetes	1	1	19

Lars‐Olof Hattenbach

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials Jeffrey S. Heier, Eleonora M. Lad, Frank G. Holz, The Lancet Ocular DiseaseOphthalmologyAge-related DiseasesGeographic AtrophyAge-related Macular Degeneration	2023	372
PDE3A mutations cause autosomal dominant hypertension with brachydactyly Philipp G. Maass, Friedrich C. Luft, Carolin Schächterle, Nature Genetics HypertensionPde3a MutationsGenetic DisorderAntihypertensive TherapyGenetics	2015	169
Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions Lars‐Olof Hattenbach, Christina M. Klais, Frank Koch, Ophthalmology ThrombosisIntravitreous InjectionVascular SurgeryHemostasisTissue Plasminogen Activator	2001	161
Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 18-Month Results of the Phase 3 GALILEO Study Yuichiro Ogura, Johann Roider, Jean‐François Korobelnik, American Journal of Ophthalmology Ocular DiseaseVitreous BodyOphthalmologyGalileo StudyIntravitreal Aflibercept	2014	158
Intravenous Thrombolysis With Low-dose Recombinant Tissue Plasminogen Activator in Central Retinal Artery Occlusion Lars‐Olof Hattenbach, I. Scharrer, H. Baatz American Journal of Ophthalmology ThrombosisOcular DiseaseRetinaVitreous BodyOphthalmology	2008	120
Risk Factors for Complications After Congenital Cataract Surgery without Intraocular Lens Implantation in the First 18 Months of Life Marc Lüchtenberg, Thomas Kohnen, Lars‐Olof Hattenbach American Journal of Ophthalmology Intraocular Lens ImplantationCongenital Cataract SurgeryOphthalmic SurgeryOcular DiseaseOphthalmology	2008	98
Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6‐month follow‐up – The SOLO study Athanasios Bezatis, Georg Spital, Fabian Höhn, Acta Ophthalmologica	2013	89
Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study Hans Hoerauf, Nicolas Feltgen, Eva‐Maria Paulus, American Journal of Ophthalmology Diabetic RetinopathyOcular DiseaseVitreous BodyComrade COphthalmology	2016	85
Incidence of posterior vitreous detachment after cataract surgery Alireza Mirshahi, Fabian Hoehn, Katrin Lorenz, Journal of Cataract & Refractive Surgery	2009	78
Coagulation disorders and the risk of retinal vein occlusion I. Scharrer, Marc Lüchtenberg, Lars‐Olof Hattenbach Thrombosis and Haemostasis Family HistoryRetinal Vein OcclusionLogistic AnalysisThrombosisVenous Disease Treatment	2009	72

Page 1